Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20584606 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL20584607 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL22982867 | 0.84 | SMN1; SMN2 (0.38) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL23006349 | 0.81 | SMN1; SMN2 (0.38) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL17064457 | 0.80 | ACHE (0.37) | KMT2ALMNAKDM4E | |
| SCHEMBL18623191 | 0.80 | ACHE (0.37) | KMT2ALMNAKDM4E | |
| SCHEMBL17064890 | 0.80 | ACHE (0.37) | KMT2ALMNAKDM4E | |
| SCHEMBL17064520 | 0.78 | MAPT (0.39) | SMN1; SMN2NPC1KMT2ACHRNB2CHRNB4 | |
| SCHEMBL18604794 | 0.78 | MAPT (0.39) | SMN1; SMN2NPC1KMT2ACHRNB2CHRNB4 | |
| SCHEMBL18623202 | 0.78 | MAPT (0.39) | SMN1; SMN2NPC1KMT2ACHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807605-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807605-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4019022-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11066360-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200361867-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2020-11-19 | — | — | US | disclosed |
| US-10562850-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066360-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | SMN1; SMN2 3221/4885NPC1 473/4885RAB9A 2232/4885 |
| US-10562850-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | SMN1; SMN2 3221/4885NPC1 473/4885RAB9A 2232/4885 |
| US-11807605-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | SMN1; SMN2 3221/4885NPC1 473/4885RAB9A 2232/4885 |
| US-20200361867-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | SMN1; SMN2 3221/4885NPC1 473/4885RAB9A 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.